ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H (HK:1541) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
ImmuneOnco Biopharmaceuticals has announced the successful dosing of the first patient in its Phase III trial of IMM01 (Timdarpacept) combined with azacitidine for treating chronic myelomonocytic leukemia (CMML). This study is notable as it is the first of its kind targeting CD47 for CMML. The company holds global intellectual property rights for IMM01, showcasing its innovative approach in the biopharmaceutical market.
For further insights into HK:1541 stock, check out TipRanks’ Stock Analysis page.